Nitrosalicyl-imine-chitosan hydrogels based drug delivery systems for long term sustained release in local therapy

2019 ◽  
Vol 536 ◽  
pp. 196-207 ◽  
Author(s):  
Anda Mihaela Craciun ◽  
Liliana Mititelu Tartau ◽  
Mariana Pinteala ◽  
Luminita Marin
Keyword(s):  
Drug Delivery ◽  
Sustained Release ◽  
Drug Delivery Systems ◽  
Local Therapy ◽  
Delivery Systems ◽  
Chitosan Hydrogels

scholarly journals Sustained-release drug delivery systems for the treatment of glaucoma

2021 ◽  
Vol 14 (1) ◽  
pp. 148-159
Author(s):  
Natasha P. Kesav ◽  
◽  
Monica K. Ertel ◽  
Leonard K. Seibold ◽  
Malik Y. Kahook ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Sustained Release ◽  
Targeted Delivery ◽  
Drug Delivery Systems ◽  
Patient Adherence ◽  
The United States ◽  
Delivery Systems ◽  
Release Drug ◽  
Systemic Side Effects

Glaucoma, a leading cause of irreversible blindness, affects more than 64 million people worldwide and is expected to grow in number due to the aging global population and enhanced methods of detection. Although topical therapies are often effective when used as prescribed, the drawbacks of current medical management methods include poor patient adherence, local and systemic side effects, and in some cases, limited therapeutic efficacy. Novel ocular drug delivery platforms promise to deliver differentiated drug formulations with targeted delivery leveraging patient-independent administration. Several platforms are in various stages of development with promising pre-clinical and clinical data. The Bimatoprost Sustained Release (SR) intracameral implant was approved in the United States in March of 2020, making it the first long-term injectable therapy available for the treatment of glaucoma. This review aims to provide an update on novel sustained release drug delivery systems that are available today as well as those that might be commercialized in coming years.

scholarly journals Electrospun organic–inorganic nanohybrids as sustained release drug delivery systems

2017 ◽  
Vol 5 (46) ◽  
pp. 9165-9174 ◽  
Author(s):  
Yanshan Gao ◽  
Tian Wei Teoh ◽  
Qiang Wang ◽  
Gareth R. Williams
Keyword(s):  
Drug Delivery ◽  
Drug Release ◽  
Sustained Release ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Release Drug

Novel organic–inorganic nanohybrids have been prepared, and are found to provide long-term extended drug release.

Development and Evaluation of Sustained Release Lipid Nanocarriers for Curcumin

2020 ◽  
Vol 5 (3) ◽  
pp. 224-235
Author(s):  
Harshal A. Pawar ◽  
Bhagyashree D. Bhangale
Keyword(s):  
Drug Delivery ◽  
Sustained Release ◽  
Drug Delivery Systems ◽  
Biological Activities ◽  
Curcuma Longa ◽  
Research Work ◽  
Elimination Rate ◽  
Delivery Systems ◽  
Physicochemical Stability ◽  
Wide Range

Background: Lipid based excipients have increased acceptance nowadays in the development of novel drug delivery systems in order to improve their pharmacokinetic profiles. Drugs encapsulated in lipids have enhanced stability due to the protection they experience in the lipid core of these nano-formulations. Phytosomes are newly discovered drug delivery systems and novel botanical formulation to produce lipophilic molecular complex which imparts stability, increases absorption and bioavailability of phytoconstituent. Curcumin, obtained from turmeric (Curcuma longa), has a wide range of biological activities. The poor solubility and wettability of curcumin are responsible for poor dissolution and this, in turn, results in poor bioavailability. To overcome these limitations, the curcumin-loaded nano phytosomes were developed to improve its physicochemical stability and bioavailability. Objective: The objective of the present research work was to develop nano-phytosomes of curcumin to improve its physicochemical stability and bioavailability. Methods: Curcumin-loaded nano phytosomes were prepared by using phospholipid Phospholipon 90 H using a modified solvent evaporation method. The developed curcumin nano phytosomes were evaluated by particle size analyzer and differential scanning calorimetry (DSC). Results: Results indicated that phytosomes prepared using curcumin and lipid in the ratio of 1:2 show good entrapment efficiency. The obtained curcumin phytosomes were spherical in shape with a size less than 100 nm. The prepared nano phytosomal formulation of curcumin showed promising potential as an antioxidant. Conclusion: The phytosomal complex showed sustained release of curcumin from vesicles. The sustained release of curcumin from phytosome may improve its absorption and lowers the elimination rate with an increase in bioavailability.

BioMEMS Technologies for Regenerative Medicine

2008 ◽  
Vol 1139 ◽  
Author(s):  
Jeffrey T. Borenstein
Keyword(s):  
Drug Delivery ◽  
Regenerative Medicine ◽  
Drug Delivery Systems ◽  
Ex Vivo ◽  
Delivery Systems ◽  
Organ Shortage ◽  
Engineered Tissues ◽  
Drug Concentrations

AbstractThe emergence of BioMEMS fabrication technologies such as soft lithography, micromolding and assembly of 3D structures, and biodegradable microfluidics, are already making significant contributions to the field of regenerative medicine. Over the past decade, BioMEMS have evolved from early silicon laboratory devices to polymer-based structures and even biodegradable constructs suitable for a range of ex vivo and in vivo applications. These systems are still in the early stages of development, but the long-term potential of the technology promises to enable breakthroughs in health care challenges ranging from the systemic toxicity of drugs to the organ shortage. Ex vivo systems for organ assist applications are emerging for the liver, kidney and lung, and the precision and scalability of BioMEMS fabrication techniques offer the promise of dramatic improvements in device performance and patient outcomes.Ultimately, the greatest benefit from BioMEMS technologies will be realized in applications for implantable devices and systems. Principal advantages include the extreme levels of achievable miniaturization, integration of multiple functions such as delivery, sensing and closed loop control, and the ability of precision microscale and nanoscale features to reproduce the cellular microenvironment to sustain long-term functionality of engineered tissues. Drug delivery systems based on BioMEMS technologies are enabling local, programmable control over drug concentrations and pharmacokinetics for a broad spectrum of conditions and target organs. BioMEMS fabrication methods are also being applied to the development of engineered tissues for applications such as wound healing, microvascular networks and bioartificial organs. Here we review recent progress in BioMEMS-based drug delivery systems, engineered tissue constructs and organ assist devices for a range of ex vivo and in vivo applications in regenerative medicine.

scholarly journals Applicability of a Modified Rat Model of Acute Arthritis for Long-Term Testing of Drug Delivery Systems

Pharmaceutics ◽  
2019 ◽  
Vol 11 (2) ◽  
pp. 70 ◽  
Author(s):  
Imke Rudnik-Jansen ◽  
Nina Woike ◽  
Suzanne de Jong ◽  
Sabine Versteeg ◽  
Marja Kik ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Total Duration ◽  
Delivery Systems ◽  
Pain Behavior ◽  
Streptococcal Cell Wall ◽  
Arthritis Model ◽  
Acute Arthritis ◽  
Analgesic Effects

Episodes of inflammation and pain are predominant features of arthritic joint diseases. Drug delivery systems (DDS) could reduce inflammation and pain long-term without chances of infection upon multiple injections. To allow for long-term evaluation of DDS, we modified a previously published acute arthritis model by extending follow-up periods between flare-ups. Unilateral synovial inflammation of the knee was induced by intra-articular injection of streptococcal cell wall peptidoglycan polysaccharide (PGPS), and flare-ups were induced by intravenous PGPS injections every 4 weeks for a total duration of 84 days. In PGPS-reactivated animals, joint swelling, pain behavior, post mortem synovitis, and osteophyte formation were notable features. Hepatitis, splenitis and inflammation of non-primed joints were observed as systemic side effects. To test the applicability of the modified arthritis model for long-term testing of DDS, the duration of anti-inflammatory and analgesic effects of a corticosteroid released from two different polymer-based platforms was evaluated. The current modified arthritis model has good applicability for testing of DDS for a prolonged period of time. Furthermore, the novel autoregulatory polyesteramide (PEA) microsphere platform releasing triamcinolone acetonide (TAA) was benchmarked against poly lactic-co-glycolic acid (PLGA) and reduced joint swelling and pain behavior more potently compared to TAA-loaded PLGA microspheres.

Physical characterizations and sustained release profiling of gastroretentive drug delivery systems with improved floating and swelling capabilities

2013 ◽  
Vol 441 (1-2) ◽  
pp. 162-169 ◽  
Author(s):  
Ying-Chen Chen ◽  
Hsiu-O Ho ◽  
Tzu-Yu Lee ◽  
Ming-Thau Sheu
Keyword(s):  
Drug Delivery ◽  
Sustained Release ◽  
Drug Delivery Systems ◽  
Delivery Systems

Imprinted hydrophilic nanospheres as drug delivery systems for 5-fluorouracil sustained release

2009 ◽  
Vol 17 (1) ◽  
pp. 72-77 ◽  
Author(s):  
G. Cirillo ◽  
F. Iemma ◽  
F. Puoci ◽  
O. I. Parisi ◽  
M. Curcio ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Sustained Release ◽  
Drug Delivery Systems ◽  
Delivery Systems

Comparison of chitosan microsphere versus O-carboxymethyl chitosan microsphere for drug delivery systems

2017 ◽  
Vol 32 (5) ◽  
pp. 469-486 ◽  
Author(s):  
Gang Zhou ◽  
Jing Zhang ◽  
Jun Tai ◽  
Qianyi Han ◽  
Lei Wang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Release ◽  
Sustained Release ◽  
Drug Delivery Systems ◽  
Controlled Drug Delivery ◽  
Delivery Systems ◽  
Carboxymethyl Chitosan ◽  
Cross Linking ◽  
Chitosan Microspheres ◽  
Chitosan Microsphere

The development of controlled drug delivery systems for bone regeneration, especially microspheres, has become a research hotspot in recent years. Chitosan and its derivative O-carboxymethyl chitosan have been considered to be an effective way for controlled drug delivery due to their nontoxicity and biodegradability. Currently, most of the studies have researched on synthesizing and characterizing chitosan and O-carboxymethyl chitosan. However, few studies have focused on the differences between chitosan microspheres and O-carboxymethyl chitosan microspheres directly. In this study, chitosan and O-carboxymethyl chitosan microspheres were developed by water-in-oil emulsification cross-linking method using vanillin as the cross-linking agent, and then their physicochemical properties were evaluated by Fourier transform infrared spectroscopy, scanning electron microscopy, and in vitro release testing. The results showed that O-carboxymethyl chitosan was successfully modified by adding carboxymethyl group at the chitosan C6 position.The particle size of chitosan microspheres (50–90 µm) was significantly larger than that of O-carboxymethyl chitosan microspheres (10–50 µm), and the drug release profile of O-carboxymethyl chitosan microspheres showed larger initial burst release within the first day and sustained release at the fourth day, while chitosan microspheres showed sustained release at the seventh day. In addition, Cell Counting Kit-8 assay showed that MC3T3-E1 proliferated well and highly expressed the alkaline phosphatase marker protein on both chitosan and O-carboxymethyl chitosan microspheres. Overall, both chitosan and O-carboxymethyl chitosan microspheres showed good biocompatibility, and chitosan microspheres were superior to O-carboxymethyl chitosan microspheres. Moreover, the different drug release rates suggest that chitosan and O-carboxymethyl chitosan microspheres have the potential to be used for the repair of different bone defects.

Sign in / Sign up

Export Citation Format

Share Document